Tatsuhiko Azegami

Dr. Tatsuhiko Azegami

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Vaccine
Verified
Journal Article
Closed access
ALAayam Lamichhane
Aayam Lamichhane
TATatsuhiko Azegami
Tatsuhiko Azegami
HKHiroshi Kiyono
Hiroshi Kiyono

9 June 2014 in International Immunology
Verified
Journal Article
Closed access
PDF file
TATatsuhiko Azegami
Tatsuhiko Azegami
YYYoshikazu Yuki
Yoshikazu Yuki
HKHiroshi Kiyono
Hiroshi Kiyono
The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.

8 May 2014 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
KHKaori Hayashi
Kaori Hayashi
HSHiroyuki Sasamura
Hiroyuki Sasamura
MNMari Nakamura
Mari Nakamura
TATatsuhiko Azegami
Tatsuhiko Azegami
HOHideyo Oguchi
Hideyo Oguchi
HIHiroshi Itoh
Hiroshi Itoh
The transcription factor Kruppel-like factor 4 (KLF4) has the ability, along with other factors, to reprogram somatic cells into induced pluripotent stem (iPS) cells. Here, we determined that KLF4 is expressed in kidney glomerular podocytes and is decreased in both animal models and humans exhibiting a proteinuric. Transient restoration of KLF4 expression in podocytes of diseased glomeruli in vivo, either by gene transfer or transgenic expression, resulted in a sustained increase in nephrin expression and a decrease in albuminuria. In mice harboring podocyte-specific deletion of Klf4, adriamycin-induced proteinuria was substantially exacerbated, although these animals displayed minimal phenotypical changes prior to adriamycin administration. KLF4 overexpression in cultured human podocytes increased expression of nephrin and other epithelial markers and reduced mesenchymal gene expression. DNA methylation profiling and bisulfite genomic sequencing revealed that KLF4 expression reduced methylation at the nephrin promoter and the promoters of other epithelial markers; however, methylation was increased at the promoters of genes encoding mesenchymal markers, suggesting selective epigenetic regulation of podocyte gene expression. Together, these results suggest that KLF4 epigenetically modulates podocyte phenotype and function and that the podocyte epigenome can be targeted for direct intervention and reduction of proteinuria.

1 October 2015 in Kidney International
Verified
Journal Article
Closed access
KHKaori Hayashi
Kaori Hayashi
HSHiroyuki Sasamura
Hiroyuki Sasamura
MNMari Nakamura
Mari Nakamura
YSYusuke Sakamaki
Yusuke Sakamaki
TATatsuhiko Azegami
Tatsuhiko Azegami
HIHiroshi Itoh
Hiroshi Itoh

15 November 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
TATatsuhiko Azegami
Tatsuhiko Azegami
KUKeiko Uchida
Keiko Uchida
MTMitsuaki Tokumura
Mitsuaki Tokumura
MMMasaaki Mori
Masaaki Mori
Hypertension is the most common non-communicable disease among adults and is the most important modifiable risk factor for premature cardiovascular disease. The increasing worldwide burden of hypertension is a major global health issue. Early prevention with lifestyle modification or pharmaceutical treatment reduces the incidence of hypertension and the risk of subsequent cardiovascular disease. Therefore, identification of young persons at risk for hypertension has the obvious benefit of providing a chance for early intervention. Previous studies have demonstrated the positive association of elevated childhood blood pressure with hypertension in adulthood. Accumulated evidence also indicates the possibility that elevated pediatric blood pressure is associated with increased risk of future cardiovascular disease. In this article, we review the tracking of blood pressure from childhood to adulthood and emphasize the importance of pediatric blood pressure monitoring and control for predicting and preventing adult hypertension and cardiovascular disease.

1 January 2015 in Proceedings of the Japan Academy, Series B
Verified
Journal Article
Open access
HKHiroshi Kiyono
Hiroshi Kiyono
TATatsuhiko Azegami
Tatsuhiko Azegami
The oral cavity is the beginning of the aero-digestive tract, which is covered by mucosal epithelium continuously under the threat of invasion of pathogens, it is thus protected by the mucosal immune system. In the early phase of our scientific efforts for the demonstration of mucosal immune system, dental science was one of major driving forces due to their foreseeability to use oral immunity for the control of oral diseases. The mucosal immune system is divided functionally into, but interconnected inductive and effector sites. Intestinal Peyer's patches (PPs) are an inductive site containing antigen-sampling M cells and immunocompetent cells required to initiate antigen-specific immune responses. At effector sites, PP-originated antigen-specific IgA B cells become plasma cells to produce polymeric IgA and form secretory IgA by binding to poly-Ig receptor expressed on epithelial cells for protective immunity. The development of new-generation mucosal vaccines, including the rice-based oral vaccine MucoRice, on the basis of the coordinated mucosal immune system is a promising strategy for the control of mucosal infectious diseases.